Melola Discovery

← Melola Discovery

Jurnal SINTA 1

The Effect of Adjuvant Therapy on Metabolic Syndrome in Schizophrenia Patients at Madani Hospital

Journal of Public Health and Pharmacy · Vol. 4 No. 3 (2024) · hlm. 280–289

DOI
10.56338/jphp.v4i3.5900
ISSN
2775-4952
Terbit
2024-11-05
Penerbit
Pusat Pengembangan Teknologi Informasi dan Jurnal Universitas Muhammadiyah Palu
Bahasa
eng

Abstrak

Background: Schizophrenia is a mental disorder that impacts behavior, emotions, and communication. In recent years, atypical antipsychotics have been increasingly prescribed because they significantly reduce both positive and negative symptoms. However, the long-term effects of atypical can cause metabolic syndrome. Additional therapy is provided to maximize the primary therapy and reduce the side effects. Method: This study used a quasi-experimental design with a single-blind, pretest-posttest approach. Patients who had been using atypical antipsychotics, either monotherapy or combination therapy, for more than 3 were examined pretest to determine metabolic syndrome levels. Group A received adjuvant therapy, while Group B did not receive adjuvant therapy. Based on this data, an analysis of the reduction in metabolic syndrome categories was conducted. Result: The percentage of schizophrenia patients by gender was dominated by males (60%). By age, the majority were adults (87%). In Group A, the incidence of metabolic syndrome decreased from 53% in the pretest to 40% in the posttest after being given vitamin A, B, and folic acid therapy. The most commonly used other medication was THP (38%). Conclusion: The administration of adjuvant therapy with vitamins A, B, E, and folic acid can reduce the value of one or two of the five metabolic syndrome criteria for schizophrenia patients (p = 0.052) compared to the group of patients who did not receive vitamins A, B, E, and folic acid adjuvant therapy. Future research should use a longer duration to observe the effects of vitamins A, B, E, and folic acid and evaluate their therapeutic doses. Additionally, it should narrow down the criteria for medication use, focusing solely on the atypical antipsychotic’s clozapine or olanzapine.

Kata kunci

Jaringan kolaborasi para penulis

19 penulis · 58 tautan kepenulisan bersama · 3 lintas organisasi

Arahkan kursor atau ketuk sebuah nama untuk menyorot rekan penulisnya. Klik dua kali untuk membuka halaman penulis.

  • Sekolah Tinggi Ilmu Farmasi Pelita Mas Palu
  • Tadulako University
  • Afiliasi tidak diketahui
  • Organisasi berbeda
  • Organisasi sama
  • Afiliasi tidak diketahui
  • Garis lebih tebal = lebih banyak artikel bersama · lingkaran lebih besar = lebih banyak artikel
Tampilkan sebagai tabel
Rekan penulisOrganisasiArtikel bersama
Al'vira GunawanSekolah Tinggi Ilmu Farmasi Pelita Mas Palu2
Muh. Thamrin TahirAfiliasi tidak diketahui2
Syafika AlaydrusSekolah Tinggi Ilmu Farmasi Pelita Mas Palu2
Nani Astria PolontaloAfiliasi tidak diketahui2
Magfirah MagfirahSekolah Tinggi Ilmu Farmasi Pelita Mas Palu1
Miranti MirantiTadulako University1
Athia Kurnia KasimAfiliasi tidak diketahui1
I Made DipayanaSekolah Tinggi Ilmu Farmasi Pelita Mas Palu1
Nur IkhwanSekolah Tinggi Ilmu Farmasi Pelita Mas Palu1
Joni TandiSekolah Tinggi Ilmu Farmasi Pelita Mas Palu1
Tien Wahyu HandayaniSekolah Tinggi Ilmu Farmasi Pelita Mas Palu1
Viani AnggiSekolah Tinggi Ilmu Farmasi Pelita Mas Palu1
Vidya ChristinSekolah Tinggi Ilmu Farmasi Pelita Mas Palu1
Magfiroh MagfirohSekolah Tinggi Ilmu Farmasi Pelita Mas Palu1
Recky PatalaSekolah Tinggi Ilmu Farmasi Pelita Mas Palu1

Afiliasi berasal dari OpenAlex; metadata OAI-PMH jurnal tidak memuatnya. Penulis tanpa ID OpenAlex dicocokkan berdasarkan nama, sehingga dua orang bisa tergabung atau satu orang bisa terpisah.

Sumber metadata: OAI-PMH (metadata jurnal) https://jurnal.unismuhpalu.ac.id/index.php/jphp/oai, pertama di-harvest 9 Nov 2026, terakhir terlihat 16 Nov 2026.
Metadata asli (oai_dc)
<oai_dc:dc xmlns="http://www.openarchives.org/OAI/2.0/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/  http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
	<dc:title xml:lang="en-US">The Effect of Adjuvant Therapy on Metabolic Syndrome in Schizophrenia Patients at Madani Hospital </dc:title>
	<dc:creator>Kurnia Utami, Indah</dc:creator>
	<dc:creator>Yasinta Rakanita</dc:creator>
	<dc:creator>Patricia Novina Nurak</dc:creator>
	<dc:creator>Niluh Puspita Dewi</dc:creator>
	<dc:subject xml:lang="en-US">Adjuvant</dc:subject>
	<dc:subject xml:lang="en-US">Atypical</dc:subject>
	<dc:subject xml:lang="en-US">Schizophrenia</dc:subject>
	<dc:description xml:lang="en-US">Background: Schizophrenia is a mental disorder that impacts behavior, emotions, and communication. In recent years, atypical antipsychotics have been increasingly prescribed because they significantly reduce both positive and negative symptoms. However, the long-term effects of atypical can cause metabolic syndrome. Additional therapy is provided to maximize the primary therapy and reduce the side effects.
Method: This study used a quasi-experimental design with a single-blind, pretest-posttest approach. Patients who had been using atypical antipsychotics, either monotherapy or combination therapy, for more than 3 were examined pretest to determine metabolic syndrome levels. Group A received adjuvant therapy, while Group B did not receive adjuvant therapy. Based on this data, an analysis of the reduction in metabolic syndrome categories was conducted. &amp;nbsp;
Result: The percentage of schizophrenia patients by gender was dominated by males (60%). By age, the majority were adults (87%). In Group A, the incidence of metabolic syndrome decreased from 53% in the pretest to 40% in the posttest after being given vitamin A, B, and folic acid therapy. The most commonly used other medication was THP (38%).
Conclusion: The administration of adjuvant therapy with vitamins A, B, E, and folic acid can reduce the value of one or two of the five metabolic syndrome criteria for schizophrenia patients (p = 0.052) compared to the group of patients who did not receive vitamins A, B, E, and folic acid adjuvant therapy. Future research should use a longer duration to observe the effects of vitamins A, B, E, and folic acid and evaluate their therapeutic doses. Additionally, it should narrow down the criteria for medication use, focusing solely on the atypical antipsychotic’s clozapine or olanzapine.</dc:description>
	<dc:publisher xml:lang="en-US">Pusat Pengembangan Teknologi Informasi dan Jurnal Universitas Muhammadiyah Palu</dc:publisher>
	<dc:date>2024-11-05</dc:date>
	<dc:type>info:eu-repo/semantics/article</dc:type>
	<dc:type>info:eu-repo/semantics/publishedVersion</dc:type>
	<dc:format>application/pdf</dc:format>
	<dc:identifier>https://jurnal.unismuhpalu.ac.id/index.php/jphp/article/view/5900</dc:identifier>
	<dc:identifier>10.56338/jphp.v4i3.5900</dc:identifier>
	<dc:source xml:lang="en-US">Journal of Public Health and Pharmacy; Vol. 4 No. 3 (2024); 280-289</dc:source>
	<dc:source>2775-4952</dc:source>
	<dc:language>eng</dc:language>
	<dc:relation>https://jurnal.unismuhpalu.ac.id/index.php/jphp/article/view/5900/4556</dc:relation>
	<dc:rights xml:lang="en-US">Copyright (c) 2024 Journal of Public Health and Pharmacy</dc:rights>
</oai_dc:dc>